THERAPEUTIC AGENT FOR AUTOIMMUNE ENTEROPATHY
PROBLEM TO BE SOLVED: To prepare the subject therapeutic agent, comprising a trypsin inhibitor as an active ingredient and useful for treating Crohn diseases, idiopathic ulcerative colitis and intestinal type Behcet diseases. SOLUTION: This therapeutic agent for autoimmune enteropathies comprises a...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | YAKIDA ASAKUNI |
description | PROBLEM TO BE SOLVED: To prepare the subject therapeutic agent, comprising a trypsin inhibitor as an active ingredient and useful for treating Crohn diseases, idiopathic ulcerative colitis and intestinal type Behcet diseases. SOLUTION: This therapeutic agent for autoimmune enteropathies comprises a trypsin inhibitor as an active ingredient. For example, a human urine-derived trypsin inhibitor which is a glycoprotein, having 65,000-70,000 molecular weight and separated and purified from a human urine, aprotinin, etc., that are the glycoprotein extracted from the bovine lungs or parotid glands are cited as the inhibitor. A steroid is preferably used together with the trypsin inhibitor to enhance therapeutic effects on autoimmune enteropathies. For example, prednisolone and paramethasone are cited as the steroid. The objective therapeutic agent is preferably intraarterially or intravenously administered. For example, the dose thereof is 10,000-1,000,000 units expressed in terms of the trypsin inhibitor and the daily dose thereof is 0.1-100mg expressed in terms of the steroid. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPH09183736A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPH09183736A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPH09183736A3</originalsourceid><addsrcrecordid>eNrjZNAJ8XANcgxwDQ3xdFZwdHf1C1Fw8w9ScAwN8ff09Q31c1UACrkG-Qc4hnhE8jCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSSeK8ADwNLQwtjc2MzR2Ni1AAAwPwlyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>THERAPEUTIC AGENT FOR AUTOIMMUNE ENTEROPATHY</title><source>esp@cenet</source><creator>YAKIDA ASAKUNI</creator><creatorcontrib>YAKIDA ASAKUNI</creatorcontrib><description>PROBLEM TO BE SOLVED: To prepare the subject therapeutic agent, comprising a trypsin inhibitor as an active ingredient and useful for treating Crohn diseases, idiopathic ulcerative colitis and intestinal type Behcet diseases. SOLUTION: This therapeutic agent for autoimmune enteropathies comprises a trypsin inhibitor as an active ingredient. For example, a human urine-derived trypsin inhibitor which is a glycoprotein, having 65,000-70,000 molecular weight and separated and purified from a human urine, aprotinin, etc., that are the glycoprotein extracted from the bovine lungs or parotid glands are cited as the inhibitor. A steroid is preferably used together with the trypsin inhibitor to enhance therapeutic effects on autoimmune enteropathies. For example, prednisolone and paramethasone are cited as the steroid. The objective therapeutic agent is preferably intraarterially or intravenously administered. For example, the dose thereof is 10,000-1,000,000 units expressed in terms of the trypsin inhibitor and the daily dose thereof is 0.1-100mg expressed in terms of the steroid.</description><edition>6</edition><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1997</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19970715&DB=EPODOC&CC=JP&NR=H09183736A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19970715&DB=EPODOC&CC=JP&NR=H09183736A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>YAKIDA ASAKUNI</creatorcontrib><title>THERAPEUTIC AGENT FOR AUTOIMMUNE ENTEROPATHY</title><description>PROBLEM TO BE SOLVED: To prepare the subject therapeutic agent, comprising a trypsin inhibitor as an active ingredient and useful for treating Crohn diseases, idiopathic ulcerative colitis and intestinal type Behcet diseases. SOLUTION: This therapeutic agent for autoimmune enteropathies comprises a trypsin inhibitor as an active ingredient. For example, a human urine-derived trypsin inhibitor which is a glycoprotein, having 65,000-70,000 molecular weight and separated and purified from a human urine, aprotinin, etc., that are the glycoprotein extracted from the bovine lungs or parotid glands are cited as the inhibitor. A steroid is preferably used together with the trypsin inhibitor to enhance therapeutic effects on autoimmune enteropathies. For example, prednisolone and paramethasone are cited as the steroid. The objective therapeutic agent is preferably intraarterially or intravenously administered. For example, the dose thereof is 10,000-1,000,000 units expressed in terms of the trypsin inhibitor and the daily dose thereof is 0.1-100mg expressed in terms of the steroid.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1997</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAJ8XANcgxwDQ3xdFZwdHf1C1Fw8w9ScAwN8ff09Q31c1UACrkG-Qc4hnhE8jCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSSeK8ADwNLQwtjc2MzR2Ni1AAAwPwlyg</recordid><startdate>19970715</startdate><enddate>19970715</enddate><creator>YAKIDA ASAKUNI</creator><scope>EVB</scope></search><sort><creationdate>19970715</creationdate><title>THERAPEUTIC AGENT FOR AUTOIMMUNE ENTEROPATHY</title><author>YAKIDA ASAKUNI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPH09183736A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1997</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>YAKIDA ASAKUNI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>YAKIDA ASAKUNI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>THERAPEUTIC AGENT FOR AUTOIMMUNE ENTEROPATHY</title><date>1997-07-15</date><risdate>1997</risdate><abstract>PROBLEM TO BE SOLVED: To prepare the subject therapeutic agent, comprising a trypsin inhibitor as an active ingredient and useful for treating Crohn diseases, idiopathic ulcerative colitis and intestinal type Behcet diseases. SOLUTION: This therapeutic agent for autoimmune enteropathies comprises a trypsin inhibitor as an active ingredient. For example, a human urine-derived trypsin inhibitor which is a glycoprotein, having 65,000-70,000 molecular weight and separated and purified from a human urine, aprotinin, etc., that are the glycoprotein extracted from the bovine lungs or parotid glands are cited as the inhibitor. A steroid is preferably used together with the trypsin inhibitor to enhance therapeutic effects on autoimmune enteropathies. For example, prednisolone and paramethasone are cited as the steroid. The objective therapeutic agent is preferably intraarterially or intravenously administered. For example, the dose thereof is 10,000-1,000,000 units expressed in terms of the trypsin inhibitor and the daily dose thereof is 0.1-100mg expressed in terms of the steroid.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_JPH09183736A |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | THERAPEUTIC AGENT FOR AUTOIMMUNE ENTEROPATHY |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A28%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=YAKIDA%20ASAKUNI&rft.date=1997-07-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPH09183736A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |